PET/CT plays a critical role in evaluating patients with relapsed/refractory multiple myeloma (RRMM) undergoing B‐cell maturation antigen (BCMA)‐directed CAR T cell therapy. Here, TNFRSF17 is linked to plasma cell myeloma.